SI2060569T1 - Metansulfonat etilestra 3-((2-((4-heksioloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzmidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline hemihidrat in njegova uporaba kot zdravilo - Google Patents

Metansulfonat etilestra 3-((2-((4-heksioloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzmidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline hemihidrat in njegova uporaba kot zdravilo

Info

Publication number
SI2060569T1
SI2060569T1 SI200431794T SI200431794T SI2060569T1 SI 2060569 T1 SI2060569 T1 SI 2060569T1 SI 200431794 T SI200431794 T SI 200431794T SI 200431794 T SI200431794 T SI 200431794T SI 2060569 T1 SI2060569 T1 SI 2060569T1
Authority
SI
Slovenia
Prior art keywords
methyl
hexyloxycarbonylamino
benzimidazol
phenylamino
imino
Prior art date
Application number
SI200431794T
Other languages
English (en)
Inventor
Peter Sieger
Rainer Sobotta
Rolf Schmid
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34202202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2060569(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SI2060569T1 publication Critical patent/SI2060569T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
SI200431794T 2003-08-29 2004-08-24 Metansulfonat etilestra 3-((2-((4-heksioloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzmidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline hemihidrat in njegova uporaba kot zdravilo SI2060569T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10339862A DE10339862A1 (de) 2003-08-29 2003-08-29 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP09153155A EP2060569B1 (de) 2003-08-29 2004-08-24 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat-Hemihydrat und dessen Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
SI2060569T1 true SI2060569T1 (sl) 2012-01-31

Family

ID=34202202

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200431177T SI1660482T1 (sl) 2003-08-29 2004-08-24 Metansulfonat etilestra 3-((2-(4-(heksiloksikarbonilamino-imino-metil)- fenilamino)-metil)-1-metil-1H-benzimidazol-5-karbonil)-piridin-2-il- amino-propionske kisline in njegova uporaba kot zdravilo
SI200431794T SI2060569T1 (sl) 2003-08-29 2004-08-24 Metansulfonat etilestra 3-((2-((4-heksioloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzmidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline hemihidrat in njegova uporaba kot zdravilo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200431177T SI1660482T1 (sl) 2003-08-29 2004-08-24 Metansulfonat etilestra 3-((2-(4-(heksiloksikarbonilamino-imino-metil)- fenilamino)-metil)-1-metil-1H-benzimidazol-5-karbonil)-piridin-2-il- amino-propionske kisline in njegova uporaba kot zdravilo

Country Status (36)

Country Link
US (2) US20050234104A1 (sl)
EP (2) EP1660482B1 (sl)
JP (2) JP5348842B2 (sl)
KR (1) KR101331039B1 (sl)
CN (2) CN102167695B (sl)
AR (2) AR045520A1 (sl)
AT (2) ATE529420T1 (sl)
AU (2) AU2004274139B2 (sl)
BR (1) BRPI0413849A (sl)
CA (2) CA2749579C (sl)
CO (1) CO5660265A2 (sl)
CY (2) CY1109299T1 (sl)
DE (2) DE10339862A1 (sl)
DK (2) DK2060569T3 (sl)
EA (1) EA009736B1 (sl)
EC (2) ECSP066399A (sl)
ES (2) ES2326654T3 (sl)
HK (2) HK1157760A1 (sl)
HR (2) HRP20090311T1 (sl)
IL (1) IL173885A (sl)
ME (1) ME00340B (sl)
MX (1) MXPA06001959A (sl)
MY (2) MY145632A (sl)
NO (2) NO334115B1 (sl)
NZ (2) NZ578586A (sl)
PE (1) PE20050348A1 (sl)
PL (2) PL2060569T3 (sl)
PT (2) PT2060569E (sl)
RS (2) RS53370B (sl)
SG (1) SG145734A1 (sl)
SI (2) SI1660482T1 (sl)
TW (2) TWI375674B (sl)
UA (1) UA85686C2 (sl)
UY (2) UY28493A1 (sl)
WO (1) WO2005028468A1 (sl)
ZA (1) ZA200600518B (sl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102006054005A1 (de) * 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
KR20100129281A (ko) * 2008-03-28 2010-12-08 베링거 인겔하임 인터내셔날 게엠베하 경구 투여되는 다비가트란 제형의 제조 방법
JP2011527318A (ja) * 2008-07-14 2011-10-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランを含有する医薬組成物の製造方法
US20110190352A1 (en) * 2008-08-19 2011-08-04 Boehringer Ingelheim International Gmbh Use of dabigatranetexilate for treating patients with pulmonary hypertension
CA2738883A1 (en) 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
EP2647375A1 (en) 2009-05-14 2013-10-09 Boehringer Ingelheim International Gmbh Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases
HUP1000069A2 (en) * 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
JP5801826B2 (ja) * 2010-03-01 2015-10-28 ラティオファルム ゲー・エム・ベー・ハー ダビガトランエテキシラートを含有する経口用医薬組成物
US20130149346A1 (en) 2010-03-08 2013-06-13 ratiopharm GmbH Graf-Arco-Strasse 3 Dabigatran etexilate-containing pharmaceutical composition
US20130177652A1 (en) 2010-07-01 2013-07-11 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
WO2012027543A1 (en) 2010-08-25 2012-03-01 Teva Pharmaceuticals Usa, Inc. Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
ES2550771T3 (es) 2010-09-27 2015-11-12 Ratiopharm Gmbh Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas
WO2012077136A2 (en) * 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
HUP1100244A2 (hu) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
EA201391758A1 (ru) 2011-05-24 2014-06-30 Тева Фармасьютикал Индастриз Лтд. Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
EA201400737A1 (ru) 2011-12-22 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
JP2015504903A (ja) 2012-01-24 2015-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の経口投与用ダビガトラン製剤
RU2633482C2 (ru) 2012-02-21 2017-10-12 Лабораторьос Дель Др. Эстеве, С.А. Пероральные фармацевтические композиции дабигатрана этексилата
EP2631234A1 (en) 2012-02-23 2013-08-28 Esteve Química, S.A. Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en) 2012-03-27 2013-10-03 Cadila Healthcare Limited New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
WO2013150545A2 (en) 2012-04-02 2013-10-10 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
EP2872499A1 (en) * 2012-07-16 2015-05-20 Interquim, S.A. Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates
IN2015DN01414A (sl) 2012-08-31 2015-07-03 Ranbaxy Lab Ltd
CN103664882A (zh) * 2012-09-20 2014-03-26 天津药物研究院 结晶变体形态的达比加群酯及其制备方法和用途
CN103864756B (zh) * 2012-12-11 2018-06-15 四川海思科制药有限公司 丁二磺酸达比加群酯及其制备方法和用途
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN104418840A (zh) * 2013-09-05 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯无水化合物
WO2015128875A2 (en) 2014-02-26 2015-09-03 Megafine Pharma (P) Ltd. A process for preparation of dabigatran etexilate mesylate and intermediates thereof
CN104892574A (zh) 2014-03-04 2015-09-09 浙江海正药业股份有限公司 达比加群酯甲磺酸盐的晶型及其制备方法和用途
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
CN108947966A (zh) * 2014-04-04 2018-12-07 江苏天士力帝益药业有限公司 达比加群酯甲磺酸盐新晶型及其制备方法
CN105461686A (zh) * 2014-08-25 2016-04-06 江苏豪森药业股份有限公司 制备高纯度甲磺酸达比加群酯晶型的方法
CN104825422B (zh) * 2014-09-29 2017-12-12 普济生物科技（台州）有限公司 含达比加群酯甲磺酸盐的药物组合物及其制备方法
WO2016107605A1 (zh) 2014-12-31 2016-07-07 昆明积大制药股份有限公司 药物组合物及其制备方法
CN104725360A (zh) * 2015-04-09 2015-06-24 重庆东得医药科技有限公司 一种甲磺酸达比加群酯ⅰ晶型的制备方法
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107778291A (zh) * 2016-08-31 2018-03-09 亚宝药业集团股份有限公司 一种甲磺酸达比加群酯晶型ⅱ的制备方法
AU2019371209A1 (en) 2018-10-29 2021-05-27 Huahai Us Inc Novel dipeptide compounds and uses thereof
JP2020193184A (ja) * 2019-05-30 2020-12-03 ダイト株式会社 ダビガトランエテキシラートメタンスルホン酸塩の形態ｉの製造方法
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
CN114380793B (zh) * 2020-10-20 2024-02-23 北京澳合药物研究院有限公司 一种甲磺酸达比加群酯晶型i的制备方法及其应用
US11446286B1 (en) * 2022-02-28 2022-09-20 King Faisal University Treatment of fungal infections using dabigatran etexilate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4427468A (en) * 1976-01-16 1984-01-24 Her Majesty The Queen In Right Of Canada Curable propellant binding systems with bonding agent combination
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja) 1982-02-02 1983-08-10 Fujisawa Pharmaceut Co Ltd 医薬組成物
US4675405A (en) * 1984-09-21 1987-06-23 American Home Products Corporation Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5416099A (en) * 1991-10-29 1995-05-16 Merck & Co., Inc. Fibrinogen receptor antagonists
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
JPH07509702A (ja) * 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド ペレット薬剤組成物
JPH06340619A (ja) 1993-05-03 1994-12-13 Bristol Myers Squibb Co グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19752843C2 (de) 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
PT1485094E (pt) * 2002-03-07 2012-10-09 Boehringer Ingelheim Int Forma de administração por via oral para 3-[(2-{[4- (hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil- 1h-benzimidazole-5-carbonil)-piridin-2-il-amino]-propionato de etilo ou os seus sais
DE10245624A1 (de) * 2002-09-30 2004-04-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1622621A2 (en) * 2003-04-24 2006-02-08 Boehringer Ingelheim International GmbH Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
US20050107438A1 (en) * 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
EP1609784A1 (de) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) * 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen

Also Published As

Publication number Publication date
ATE529420T1 (de) 2011-11-15
HRP20090311T1 (en) 2009-07-31
PL1660482T3 (pl) 2009-08-31
PT1660482E (pt) 2009-06-04
EA009736B1 (ru) 2008-02-28
CY1109299T1 (el) 2014-07-02
ECSP066399A (es) 2006-09-18
KR20070031830A (ko) 2007-03-20
IL173885A (en) 2015-04-30
AU2004274139B2 (en) 2010-05-13
ES2326654T3 (es) 2009-10-16
CO5660265A2 (es) 2006-07-31
MEP50608A (en) 2011-02-10
CN1845917A (zh) 2006-10-11
TWI375674B (en) 2012-11-01
CN102167695A (zh) 2011-08-31
HK1096682A1 (sl) 2007-06-08
UY32342A (es) 2011-07-29
ES2375896T3 (es) 2012-03-07
AU2004274139A1 (en) 2005-03-31
JP2007504106A (ja) 2007-03-01
AR045520A1 (es) 2005-11-02
US20050234104A1 (en) 2005-10-20
DK1660482T3 (da) 2009-08-24
HK1157760A1 (en) 2012-07-06
EP1660482B1 (de) 2009-04-29
IL173885A0 (en) 2006-07-05
TWI418553B (zh) 2013-12-11
NO20061420L (no) 2006-03-28
CN1845917B (zh) 2011-05-11
TW200512206A (en) 2005-04-01
UA85686C2 (ru) 2009-02-25
ECSP11006399A (es) 2011-12-30
AU2010201457B2 (en) 2012-05-10
NZ545984A (en) 2009-08-28
HRP20120028T1 (hr) 2012-01-31
ME00340B (me) 2011-05-10
AR073225A2 (es) 2010-10-20
ATE430145T1 (de) 2009-05-15
US20080119523A1 (en) 2008-05-22
PE20050348A1 (es) 2005-06-15
WO2005028468A1 (de) 2005-03-31
NZ578586A (en) 2011-01-28
NO20130778L (no) 2006-03-28
EP2060569B1 (de) 2011-10-19
CN102167695B (zh) 2013-06-19
BRPI0413849A (pt) 2006-10-24
CA2749579A1 (en) 2005-03-31
TW201202217A (en) 2012-01-16
MY145696A (en) 2012-03-30
EA200600381A1 (ru) 2006-08-25
CA2749579C (en) 2013-04-16
DK2060569T3 (da) 2012-01-23
PT2060569E (pt) 2011-12-29
EP1660482A1 (de) 2006-05-31
CA2537054C (en) 2011-12-06
RS53370B (en) 2014-10-31
RS20060136A (en) 2008-06-05
MXPA06001959A (es) 2006-05-17
US7932273B2 (en) 2011-04-26
KR101331039B1 (ko) 2013-11-20
CA2537054A1 (en) 2005-03-31
ZA200600518B (en) 2006-12-27
DE502004009431D1 (en) 2009-06-10
NO334115B1 (no) 2013-12-16
SG145734A1 (en) 2008-09-29
JP5348842B2 (ja) 2013-11-20
MY145632A (en) 2012-03-15
UY28493A1 (es) 2005-03-31
PL2060569T3 (pl) 2012-03-30
DE10339862A1 (de) 2005-03-24
CY1112222T1 (el) 2015-12-09
AU2010201457A1 (en) 2010-05-06
JP2011178803A (ja) 2011-09-15
JP5566332B2 (ja) 2014-08-06
SI1660482T1 (sl) 2009-10-31
EP2060569A1 (de) 2009-05-20

Similar Documents

Publication Publication Date Title
SI2060569T1 (sl) Metansulfonat etilestra 3-((2-((4-heksioloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzmidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline hemihidrat in njegova uporaba kot zdravilo
SI1658056T1 (sl) Tableta, ki vsebuje etil ester 3-((2-((4-(heksiloksikarbonilamino-imino-metil)fenilamino)-metil)-1- metil-1H-benzimidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline ali njegove soli
GB0208627D0 (en) Needle
EP1532080A4 (en) CEMENTITIOUS COMPOSITION WITH VERY FAST TAKING
HK1111417A1 (en) Quinazoline derivatives
GB0215823D0 (en) Quinazoline derivatives
IL174154A0 (en) Novel glp-1 derivatives
HK1066661A1 (en) Folder synchronization
PL377474A1 (pl) Pochodne 3H-chinazolin-4-onu
AU2003291959A8 (en) Novel glucagon antagonists
TW587703U (en) Motherboard test fixture
GB2401321B (en) Can fixture
PL374817A1 (en) Quinazoline derivatives
HK1092840A1 (en) Use of a polypeptides
GB0213598D0 (en) Carboxamides derivatives
AU2003244710A8 (en) Use of a vanilloid as an anti-snoring element
GB2388841B (en) Polymerisable heterocyclic acetylenes
GB0223399D0 (en) Receptors
AU2003304422A8 (en) Nano-laminate-based ignitors
AU156041S (en) A set of sparklers
GB0224513D0 (en) AZO compounds
GB0206966D0 (en) Semiotic signature
GB0220160D0 (en) Ethnic-friendly plasters
TW516422U (en) Device for propping up muscle for operation
TW525816U (en) Hanging scroll structure